A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1779-1785

  Kanagavel, D ^a   Pokataev, I A ^a   Fedyanin, M Y ^a   Tryakin, A A ^a   Bazin, I S ^a   Narimanov, M N ^a   Yakovleva, E S ^a   Garin, A M ^a   Tjulandin, S A ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

Gastric cancer; Prognostic factors; Prognostic model; Second Line chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; HEMOGLOBIN; MITOMYCIN C;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVARY METASTASIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMACH CANCER;

EID: 77956121489     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq032     Document Type: Article

References (28)

1. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancerbase No. 5, Version 2.0. Lyon: IARC Press 2004.
2. Correa P, Chen VW. Gastric cancer. Cancer Surv 1994; 19-20: 55-76.
3. World Health Organization. The World Health Report 2003. Geneva: WHO 2003.
4. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56: 1-9.
5. Catalano V, Labianca R, Beretta G et al. Gastric cancer. Crit Rev Oncol Hematol 2009; 71-72: 127-164.
6. Berrino F, De Angelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-783.
7. Van Cutsem E, Moiseyenko VM, Tjulandin SA et al. V325 Study Group Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006; 24: 4991-4997.
8. Roth AD, Fazio N, Stupp R et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2007; 25: 3217-3223.
9. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
10. Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol 2005; 17: 81-90.
11. Graziano F, Catalano V, Baldelli AM et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000; 11: 1263-1266.
12. Schmitz SH, Voliotis DL, Schimke J et al. Continuous 5-fluorouracil and leucovorin as a second-line therapy for advanced gastric carcinoma. Oncology 1994; 51: 502-506.
13. Barone C, Cassano A, Landriscina M et al. Bolus and infusional 5-fluorouracil combined with cisplatin in advanced gastric cancer. Oncol Rep 2000; 7: 1305-1309.
14. Vanhoeffer U, Wilke H, Weh HJ et al. Weekly high dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 1994; 5: 850-851.
15. Stathopoulos GP, Rigatos SK, Fountzilas G et al. Paclitaxel and carboplatin in pre-treated advanced gastric cancer: a phase II study. Oncol Rep 2002; 9: 89-92.
16. Ohtsu A, Yoshida S, Saito D et al. An early phase II study of 5-fluorouracil combined with cisplatinum as a second-line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 1991; 21: 120-124.
17. Chau I, Norman AR, Ross PJ. Multivariate prognostic factor analysis and secondline treatment in locally advanced and metastatic oesophago-gastric cancer-pooled analysis of 1080 patients from three multicentre randomised controlled trials using individual patient data. Proceedings of the ASCO Gastrointestinal Cancers Symposium, San Francisco, California (Abstr 5). 2004.
18. Kodera Y, Ito S, Mochizuki Y et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 2007; 27: 2667-2671.
19. Hartmann JT, Quietsch D, Daikeler T et al. Mitomycin C continuous infusion as salvage chemotherapy in pre-treated patients with advanced gastric cancer. Anticancer Drugs 1999; 10: 729-733.
20. Thuss-Patience PC, Kretzschmar A, Deist T et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2009; 27 (Suppl): 15s (Abstr 4540).
21. Chau I, Norman AR, Cunningham D et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004; 22: 2395-2403.
22. Yoshida M, Ohtsu A, Boku N et al. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol 2004; 34: 654-659.
23. Lee J, Lim T, Uhm JE et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007; 18: 886-891.
24. Catalano V, Graziano F, Santini D et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Can 2008; 99: 1402-1407.
25. Ji SH, Lim DH, Yi SY et al. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer 2009; 9: 110.
26. Park SH, Lee J, Lee SH et al. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2006; 57: 91-96.
27. Stahl M, Müller C, Köster W et al. Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy. Onkologie 2005; 28: 499-502.
28. Andreyev HJ, Norman AR, Oates J et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998; 34: 503-509.